Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Overweight at Morgan Stanley

Morgan Stanley upgraded shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) from an equal weight rating to an overweight rating in a research note published on Tuesday, Marketbeat Ratings reports. The brokerage currently has $20.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $15.00. FOLD has been the subject […]

Leave a Reply

Your email address will not be published.

Previous post Future (LON:FUTR) Upgraded by Canaccord Genuity Group to Hold
Next post HSBC Downgrades Banco Santander-Chile (NYSE:BSAC) to Hold